


The Power of Cutting-Edge Technology


Agilent is at the forefront of technology innovation to unlock the promise of precision medicine.



Technologies in bold represent current Agilent capabilities

Note: Technologies in bold may not be approved for diagnostic use.


References: 1. National Center for Biotechnology Information, U.S. National Library of Medicine. <https://www.ncbi.nlm.nih.gov> (accessed Sept. 3, 2019). 2. Universal Protein Resource, UniProt Consortium. <https://www.uniprot.org> (accessed Sept. 3, 2019). 3. O'Connor, O. A.; Bhagat, G.; Ganapathi K. A.; Kaplan, J.; Corradini, P.; Guitart, J.; Rosen, S. T.; Kuzel T. M. T-Cell Lymphomas. In *Hematology: Basic Principles and Practice*, 7th ed.; Hoffman, R., Benz, E. J., Silberstein, L. E., Heslop, H. E., Weitz, J. I., Anastasi, J., Salama, M. E., Abutalib, S. A., Eds.; Elsevier: Philadelphia, PA, 2018. 4. McCain, J. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment of BRAF-Mutated Metastatic Melanoma. *P. T.* **2013**, *38* (2), 96-108. 5. Porta, C.; Paglino, C.; Mosca, A. Targeting PI3K/Akt/mTOR Signaling in Cancer. *Front. Oncol.* **2014**, *4*, 64. 6. Galon, J.; Bruni, D. Approaches to Treat Immune Hot, Altered and Cold Tumours with Combination Immunotherapies. *Nat. Rev. Drug Discov.* **2019**, *18* (3), 197-218. 7. *Predictive Biomarkers in Oncology: Applications in Precision Medicine*; Badve, S., Kumar, G. L., Eds. Springer: Cham, Switzerland, 2019.



Note: The above graphic illustrates the range of biomarkers that are actively being studied across a large volume of clinical trials. The featured biomarkers are the top 80 identified based on an analysis of oncology trials mentioning biomarker use on ClinicalTrials.gov, recent publications, and research conducted by a variety of institutions. This list is not intended to be a complete nor comprehensive audit of biomarker research activity, and does not represent nor reflect the specific diagnostic offerings of Agilent Technologies, Inc.

The Future of Targeted Treatment

Agilent is a leading partner to drive clinical utility into proven pathways while helping to enable the next generation of predictive biomarkers.



High-throughput sequencing of novel and evolving biomarker panels, such as TMB and MSI, have the potential to further revolutionize precision medicine.

The Need for Expertise

At Agilent CDx, dedicated experts collaborate to combine experience with innovation, enabling the full potential of biomarker-driven landmark therapies.

This information is subject to change without notice.
© Agilent Technologies, Inc. 2019
Published in the USA, September 3, 2019

